Palifermin

Palifermin
Clinical data
AHFS/Drugs.com monograph
MedlinePlus a605017
Pregnancy cat.  ?
Legal status  ?
Identifiers
CAS number 162394-19-6 Y
ATC code V03AF08
DrugBank BTD00042
UNII QMS40680K6 Y
ChEMBL CHEMBL1201821 N
Chemical data
Formula C721H1142N202O204S9 
Mol. mass 16192.7 g/mol
 N(what is this?)  (verify)

Palifermin (trade name Kepivance, marketed by Biovitrum) is a human recombinant keratinocyte growth factor (KGF)[1] produced in Escherichia coli. KGF stimulates the growth of cells that line the surface of the mouth and intestinal tract.[2]

Contents

Uses

When patients with blood cancers (leukemia and lymphoma) receive high dose chemotherapy and radiation therapy to undergo bone marrow transplantation, they usually get severe oral mucositis.[3] Palifermin binds to epithelial cell-surface receptors and stimulates epithelial cell proliferation, differentiation, and upregulation of cytoprotective mechanisms. It reduces the incidence and duration of severe oral mucitis[4][5] by protecting those cells and stimulating the growth of new epithelial cells to build up the mucosal barrier.

Palifermin is also being studied in the prevention and treatment of oral mucositis and dysphagia (difficulty swallowing) in other types of cancer.[2]

Costs

Palifermin costs approximately 5,000 Euros per treatment for a 70 kg patient.[6]

References

  1. ^ Beaven AW, Shea TC (September 2007). "The effect of palifermin on chemotherapyand radiation therapy-induced mucositis: a review of the current literature". Support Cancer Ther 4 (4): 188–97. doi:10.3816/SCT.2007.n.014. PMID 18632516. http://cigjournals.metapress.com/openurl.asp?genre=article&id=doi:10.3816/SCT.2007.n.014. 
  2. ^ a b Kepivance entry in the public domain NCI Dictionary of Cancer Terms
  3. ^ Blijlevens N, Sonis S (May 2007). "Palifermin (recombinant keratinocyte growth factor-1): a pleiotropic growth factor with multiple biological activities in preventing chemotherapy- and radiotherapy-induced mucositis". Ann. Oncol. 18 (5): 817–26. doi:10.1093/annonc/mdl332. PMID 17030544. http://annonc.oxfordjournals.org/cgi/pmidlookup?view=long&pmid=17030544. 
  4. ^ Spielberger R, Stiff P, Bensinger W, et al. (December 2004). "Palifermin for oral mucositis after intensive therapy for hematologic cancers". N. Engl. J. Med. 351 (25): 2590–8. doi:10.1056/NEJMoa040125. PMID 15602019. http://content.nejm.org/cgi/pmidlookup?view=short&pmid=15602019&promo=ONFLNS19. 
  5. ^ McDonnell AM, Lenz KL (January 2007). "Palifermin: role in the prevention of chemotherapy- and radiation-induced mucositis". Ann Pharmacother 41 (1): 86–94. doi:10.1345/aph.1G473. PMID 17190850. http://www.theannals.com/cgi/pmidlookup?view=long&pmid=17190850. 
  6. ^ NEW DRUGS in TRANSPLANTATION, EBMT Meeting, France, March 2007 C. PAILLET, Pharmacist, Pharm D. C. RENZULLO, Pharmacist, Pharm D. Edouard Herriot Hospital, Lyon, FRANCE

External links

Detoxifying agents for antineoplastic treatment (V03AF)
Folic acid / methotrexate
Salts of Folinic acid (calcium folinate/calcium levofolinate, sodium folinate/sodium levofolinate)
Uric acid (TLS)
Acrolein / nitrogen mustards
Iron / anthracyclines
Alkylating agents
Keratinocyte growth factor
Palifermin

M: NEO

tsoc, mrkr

tumr, epon, para

drug (L1i/1e/V03)

 This article incorporates public domain material from the U.S. National Cancer Institute document "Dictionary of Cancer Terms".